USPSTF updates guidance on statins for primary prevention of cardiovascular disease
Feb 22, 2022
The evidence currently is insufficient for assessing the balance of benefits and harms of statin initiation for primary prevention of CVD and mortality in adults aged 76 years or older.
USPSTF: Evidence still lacking for atrial fibrillation screening
Jan 27, 2022
Evidence currently is inadequate for assessing the balance of benefits and harms of screening for atrial fibrillation in asymptomatic adults.
Four in 10 adults report heart symptoms during the pandemic
Feb 09, 2022
And one in four COVID-19 survivors says the virus affected their heart health.
Vitamin K inversely linked to risk for atherosclerotic CVD
Aug 16, 2021
Participants with diets high in vitamin K1 and vitamin K2 had a reduced risk for atherosclerotic cardiovascular disease in adjusted analyses.
Resistance exercise may be better for improving sleep
Mar 14, 2022
A self-reported increase in sleep duration was seen with resistance exercise but not aerobic exercise, combined exercise or no exercise (control).
Sodium-containing acetaminophen may raise risk for cardiovascular disease
Feb 28, 2022
An increase in cardiovascular disease and one-year mortality risks were seen with initiation of sodium-containing acetaminophen for people with and without hypertension.
USPSTF recommends statins for primary prevention of CVD in adults
Aug 24, 2022
Statin use is recommended for adults aged 40 to 75 years with at least one CVD risk factor and estimated 10-year CVD event risk of ≥10%.
Height may impact risk for disease
Jun 03, 2022
Novel associations were seen for venous circulatory disorders and peripheral neuropathy in the presence and absence of diabetes.
CVD risk factors ID’d in individuals with high fracture risk
Sep 09, 2022
The highest incidence of major adverse cardiovascular events was seen in those with incident fragility fracture.
Risk factors worsening for adults with cardiovascular disease
Aug 09, 2022
From 1999-2002 to 2015-2018, a worsening was seen in proportion with ideal HbA1c and BMI and an increase in proportion with non-HDL-C levels <100 mg/dL.